Published in Psychopharmacology (Berl) on April 24, 2003
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Review. Neurobiology of nicotine dependence. Philos Trans R Soc Lond B Biol Sci (2008) 1.62
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Nicotine administration and withdrawal affect survival in systemic inflammation models. J Appl Physiol (1985) (2008) 1.48
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology (Berl) (2006) 1.45
'Nicotine deprivation effect' in rats with intermittent 23-hour access to intravenous nicotine self-administration. Pharmacol Biochem Behav (2007) 1.25
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Exposure to nicotine and sensitization of nicotine-induced behaviors. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.19
Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology (Berl) (2004) 1.16
Genetic variability in nicotinic acetylcholine receptors and nicotine addiction: converging evidence from human and animal research. Behav Brain Res (2008) 1.14
Sex Differences in Animal Models: Focus on Addiction. Pharmacol Rev (2016) 1.09
The reinforcement-enhancing effects of nicotine: implications for the relationship between smoking, eating and weight. Physiol Behav (2011) 1.07
Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology (Berl) (2008) 1.07
Impact of tobacco regulation on animal research: new perspectives and opportunities. Nicotine Tob Res (2012) 1.01
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Nicotine withdrawal-induced deficits in trace fear conditioning in C57BL/6 mice--a role for high-affinity beta2 subunit-containing nicotinic acetylcholine receptors. Eur J Neurosci (2009) 1.00
Comparison of the behavioral effects of cigarette smoke and pure nicotine in rats. Pharmacol Biochem Behav (2010) 1.00
Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav Pharmacol (2010) 0.99
Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning. Pharmacol Biochem Behav (2007) 0.99
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Extended access to nicotine leads to a CRF1 receptor dependent increase in anxiety-like behavior and hyperalgesia in rats. Addict Biol (2013) 0.89
Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology (Berl) (2011) 0.88
Precipitated withdrawal from nicotine reduces reinforcing effects of a visual stimulus for rats. Nicotine Tob Res (2012) 0.87
Episodic withdrawal promotes psychomotor sensitization to morphine. Neuropsychopharmacology (2010) 0.87
Dissociated effects of anticipating smoking versus monetary reward in the caudate as a function of smoking abstinence. Biol Psychiatry (2013) 0.85
Intermittent nicotine exposure upregulates nAChRs in VTA dopamine neurons and sensitises locomotor responding to the drug. Eur J Neurosci (2013) 0.84
Dose, duration, and pattern of nicotine administration as determinants of behavioral dependence in rats. Psychopharmacology (Berl) (2005) 0.84
Active immunisation against nicotine blocks the reward facilitating effects of nicotine and partially prevents nicotine withdrawal in the rat as measured by dopamine output in the nucleus accumbens, brain reward thresholds and somatic signs. Naunyn Schmiedebergs Arch Pharmacol (2005) 0.83
Emergence of dormant conditioned incentive approach by conditioned withdrawal in nicotine addiction. Biol Psychiatry (2010) 0.82
Mecamylamine elicits withdrawal-like signs in rats following a single dose of nicotine. Psychopharmacology (Berl) (2012) 0.82
Both GABA(B) receptor activation and blockade exacerbated anhedonic aspects of nicotine withdrawal in rats. Eur J Pharmacol (2011) 0.82
Nicotine exposure and transgenerational impact: a prospective study on small regulatory microRNAs. Sci Rep (2014) 0.80
Nicotine withdrawal and kappa-opioid receptors. Psychopharmacology (Berl) (2009) 0.79
Baseline impulsive choice predicts the effects of nicotine and nicotine withdrawal on impulsivity in rats. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.79
Varenicline enhances dopamine release facilitation more than nicotine after long-term nicotine treatment and withdrawal. Pharmacol Res Perspect (2014) 0.77
Nicotine delivery to rats via lung alveolar region-targeted aerosol technology produces blood pharmacokinetics resembling human smoking. Nicotine Tob Res (2012) 0.76
Neuropeptide systems and new treatments for nicotine addiction. Psychopharmacology (Berl) (2016) 0.75
A Two-Day Continuous Nicotine Infusion Is Sufficient to Demonstrate Nicotine Withdrawal in Rats as Measured Using Intracranial Self-Stimulation. PLoS One (2015) 0.75
Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry (1986) 10.11
Recent advances in the pharmacotherapy of smoking. JAMA (1999) 5.10
Commitment to abstinence and acute stress in relapse to alcohol, opiates, and nicotine. J Consult Clin Psychol (1990) 3.44
Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res (2000) 3.33
Dramatic decreases in brain reward function during nicotine withdrawal. Nature (1998) 3.21
Relapse and maintenance issues for smoking cessation. Health Psychol (2000) 3.10
Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry (1991) 2.51
Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology (1991) 2.41
Smoking cessation during previous year among adults--United States, 1990 and 1991. MMWR Morb Mortal Wkly Rep (1993) 2.26
Smoking withdrawal dynamics in unaided quitters. J Abnorm Psychol (2000) 2.11
Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci U S A (1995) 2.00
Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav (1992) 1.96
Euphorigenic drugs: effects on the reward pathways of the brain. Fed Proc (1979) 1.93
Baseline factors associated with smoking cessation and relapse. MRFIT Research Group. Prev Med (1991) 1.93
Repeated episodes of ethanol withdrawal potentiate the severity of subsequent withdrawal seizures: an animal model of alcohol withdrawal "kindling". Alcohol Clin Exp Res (1993) 1.90
Severity of withdrawal symptoms as a predictor of outcome of an attempt to quit smoking. Psychol Med (1989) 1.88
Predictors of initial smoking cessation and relapse through the first 2 years of the Lung Health Study. J Consult Clin Psychol (1995) 1.86
Profiles in discouragement: two studies of variability in the time course of smoking withdrawal symptoms. J Abnorm Psychol (1998) 1.84
An investigation of self-efficacy, partner support and daily stresses as predictors of relapse to smoking in self-quitters. Addiction (1995) 1.82
A digest of memory phenomena for addiction research. Addiction (1994) 1.78
Nicotine withdrawal symptoms and psychiatric disorders: findings from an epidemiologic study of young adults. Am J Psychiatry (1992) 1.74
Nicotine skin patch treatment increases abstinence, decreases withdrawal symptoms, and attenuates rewarding effects of smoking. J Clin Psychopharmacol (1994) 1.73
Tolerance to, and dependence on, some non-opiate psychotropic drugs. Pharmacol Rev (1971) 1.71
Neurobiology of the nicotine withdrawal syndrome. Pharmacol Biochem Behav (2001) 1.67
Reward and somatic changes during precipitated nicotine withdrawal in rats: centrally and peripherally mediated effects. J Pharmacol Exp Ther (2000) 1.56
Classification and prediction of smoking relapse episodes: an exploration of individual differences. J Consult Clin Psychol (1988) 1.55
Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav (1992) 1.54
Inter-species consistency in the behavioural pharmacology of nicotine dependence. Behav Pharmacol (1999) 1.49
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Cigarette smoking prevalence, cessation and relapse. Stat Methods Med Res (1998) 1.44
Relative sensitivity to naloxone of multiple indices of opiate withdrawal: a quantitative dose-response analysis. J Pharmacol Exp Ther (1994) 1.35
Abuse liability of benzodiazepines. Pharmacol Rev (1987) 1.34
Circumstances surrounding relapse in a group of recent exsmokers. Prev Med (1985) 1.34
Abstinence effects as predictors of 28-day relapse in smokers. Addict Behav (1996) 1.33
Predictors and reasons for relapse in smoking cessation with nicotine and placebo patches. Prev Med (1993) 1.33
Chronic nicotine exposure differentially affects the function of human alpha3, alpha4, and alpha7 neuronal nicotinic receptor subtypes. J Pharmacol Exp Ther (1997) 1.29
Alcohol detoxification and withdrawal seizures: clinical support for a kindling hypothesis. Biol Psychiatry (1988) 1.28
Clinical pharmacology of nicotine. Annu Rev Med (1986) 1.25
Nicotine dependence: studies with a laboratory model. Pharmacol Biochem Behav (2001) 1.23
Effect of nicotine replacement on the cigarette withdrawal syndrome. Br J Addict (1984) 1.22
Who will relapse? Symptoms of nicotine dependence predict long-term relapse after smoking cessation. J Consult Clin Psychol (1992) 1.19
Cigarette withdrawal symptoms in adolescent smokers. Psychopharmacology (Berl) (1986) 1.19
Predictors of smoking cessation and maintenance. J Clin Psychol (1998) 1.18
Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry (2003) 1.17
Nicotine gum to help stop smoking. JAMA (1984) 1.17
Relapse prevention for smoking cessation: review and evaluation of concepts and interventions. Annu Rev Public Health (1994) 1.13
Pre-abstinence smoke intake and smoking motivation as predictors of severity of cigarette withdrawal symptoms. Psychopharmacology (Berl) (1985) 1.13
Comparative psychophysiological studies of alcoholic and nonalcoholic subjects undergoing experimentally induced ethanol intoxication. Psychosom Med (1966) 1.11
Effects of repeated withdrawal from continuous amphetamine administration on brain reward function in rats. Psychopharmacology (Berl) (2000) 1.07
The tobacco withdrawal syndrome in unaided quitters. Br J Addict (1991) 1.04
Desmethylimipramine attenuates cocaine withdrawal in rats. Psychopharmacology (Berl) (1992) 1.04
Subject characteristics and long term post-program smoking cessation. Addict Behav (1988) 1.03
Reports of smoking withdrawal symptoms over a 21 day period of abstinence. Addict Behav (1985) 1.00
Amphetamine and the reward system: evidence for tolerance and post-drug depression. Psychopharmacologia (1976) 0.99
Prospective study of factors influencing the development of craving associated with smoking cessation. Psychopharmacology (Berl) (1991) 0.97
Differential effects of withdrawal from chronic amphetamine or fluoxetine administration on brain stimulation reward in the rat--interactions between the two drugs. Psychopharmacology (Berl) (1999) 0.96
Nicotine replacement: ten-week effects on tobacco withdrawal symptoms. Psychopharmacology (Berl) (1989) 0.94
Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology (Berl) (1995) 0.93
Bromocriptine reverses the elevation in intracranial self-stimulation thresholds observed in a rat model of cocaine withdrawal. Neuropsychopharmacology (1992) 0.93
Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats. J Neurosci (1999) 0.91
Sustained nicotine exposure differentially affects alpha 3 beta 2 and alpha 4 beta 2 neuronal nicotinic receptors expressed in Xenopus oocytes. J Neurochem (1996) 0.90
Time-dependent alterations in ICSS thresholds associated with repeated amphetamine administrations. Pharmacol Biochem Behav (2000) 0.90
Clinical conditions in alcoholics during long-term abstinence: a descriptive, longitudinal treatment study. Alcohol (1985) 0.89
Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology (2003) 0.88
Preventing relapse in the treatment of nicotine addiction: current issues and future directions. J Psychoactive Drugs (1992) 0.86
Clozapine treatment attenuated somatic and affective signs of nicotine and amphetamine withdrawal in subsets of rats exhibiting hyposensitivity to the initial effects of clozapine. Biol Psychiatry (2003) 0.84
Smoking topography in a nonlaboratory environment. Int J Addict (1987) 0.83
The influence of heroin dose and route of administration on the severity of the opiate withdrawal syndrome. Addiction (1999) 0.82
Physical dependence on nicotine in gum. A placebo substitution trial. JAMA (1986) 0.81
Effects of chronic amphetamine or reserpine on self-stimulation responding: animal model of depression? Psychopharmacology (Berl) (1980) 0.81
Physical dependence on ethanol during multiple intoxication and withdrawal episodes in the rat: evidence of a potentiation. Acta Pharmacol Toxicol (Copenh) (1984) 0.81
Effect of chronic nicotine on brain stimulation reward. I. Effect of daily injections. Behav Brain Res (1998) 0.80
The effect of repeated withdrawal episodes on subsequent withdrawal severity in ethanol-treated rats. Drug Alcohol Depend (1989) 0.80
Response sensitization and depression following long-term amphetamine treatment in a self-stimulation paradigm. Psychopharmacology (Berl) (1980) 0.79
Potentiation of ethanol withdrawal by prior dependence. Psychopharmacology (Berl) (1979) 0.78
Comparison of ethanol withdrawal syndrome in humans and rats. Adv Exp Med Biol (1977) 0.78
Effects of withdrawal from long-term nicotine gum use. Psychol Med (1985) 0.77
Opiate withdrawal in the neonatal rat: relationship to duration of treatment and naloxone dose. Psychopharmacology (Berl) (2000) 0.77
Effect of chronic nicotine on brain stimulation reward. II. An escalating dose regimen. Behav Brain Res (1998) 0.77
Impairment of shuttlebox avoidance learning following repeated alcohol withdrawal episodes in rats. Pharmacol Biochem Behav (1979) 0.75
Enhanced lateral hypothalamic self-stimulation responding after chronic exposure to amphetamine. Behav Neural Biol (1980) 0.75
Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol Sci (2002) 4.02
Guidelines on nicotine dose selection for in vivo research. Psychopharmacology (Berl) (2006) 3.68
Role for hypocretin in mediating stress-induced reinstatement of cocaine-seeking behavior. Proc Natl Acad Sci U S A (2005) 3.05
Neurobiological mechanisms in the transition from drug use to drug dependence. Neurosci Biobehav Rev (2004) 2.97
Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci (2002) 2.83
Conditioned withdrawal drives heroin consumption and decreases reward sensitivity. J Neurosci (2006) 2.74
The neurobiology of anhedonia and other reward-related deficits. Trends Neurosci (2011) 2.36
The role of cystine-glutamate exchange in nicotine dependence in rats and humans. Biol Psychiatry (2008) 2.08
Nicotine self-administration acutely activates brain reward systems and induces a long-lasting increase in reward sensitivity. Neuropsychopharmacology (2006) 2.05
Primary aldosteronism in hypertensive patients: clinical implications and target therapy. Eur J Clin Invest (2014) 1.99
The ups and downs of addiction: role of metabotropic glutamate receptors. Trends Pharmacol Sci (2004) 1.90
Metabotropic glutamate 2/3 receptors in the ventral tegmental area and the nucleus accumbens shell are involved in behaviors relating to nicotine dependence. J Neurosci (2007) 1.85
The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice. Psychopharmacology (Berl) (2003) 1.83
Increased motivation for self-administered cocaine after escalated cocaine intake. Neuroreport (2003) 1.73
Circulating tumor cells in breast cancer: detection systems, molecular characterization, and future challenges. Clin Chem (2011) 1.60
NMDA receptors regulate nicotine-enhanced brain reward function and intravenous nicotine self-administration: role of the ventral tegmental area and central nucleus of the amygdala. Neuropsychopharmacology (2008) 1.57
Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. Addict Sci Clin Pract (2011) 1.57
The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats. Psychopharmacology (Berl) (2004) 1.51
Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) (2003) 1.49
Disruption of performance in the five-choice serial reaction time task induced by administration of N-methyl-D-aspartate receptor antagonists: relevance to cognitive dysfunction in schizophrenia. Biol Psychiatry (2010) 1.48
Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats. Psychopharmacology (Berl) (2001) 1.47
Metabotropic glutamate 5 receptor blockade may attenuate cocaine self-administration by decreasing brain reward function in rats. Psychopharmacology (Berl) (2004) 1.47
Diminished nicotine withdrawal in adolescent rats: implications for vulnerability to addiction. Psychopharmacology (Berl) (2006) 1.45
Nicotine withdrawal in adolescent and adult rats. Ann N Y Acad Sci (2004) 1.44
The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J Neurosci (2006) 1.40
Presence of high-risk human papillomavirus sequences in breast cancer tissues and association with histopathological characteristics. Clin Biochem (2006) 1.39
Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology (2005) 1.34
Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci (2005) 1.31
Extended access to nicotine self-administration leads to dependence: Circadian measures, withdrawal measures, and extinction behavior in rats. J Pharmacol Exp Ther (2006) 1.30
Laparoscopic surgery for adrenal tumors. A retrospective analysis. Hormones (Athens) (2006) 1.29
The GABAB receptor agonists baclofen and CGP44532 decreased nicotine self-administration in the rat. Psychopharmacology (Berl) (2003) 1.28
Chronic bupropion attenuated the anhedonic component of nicotine withdrawal in rats via inhibition of dopamine reuptake in the nucleus accumbens shell. Eur J Neurosci (2007) 1.25
Role of the glutamatergic system in nicotine dependence : implications for the discovery and development of new pharmacological smoking cessation therapies. CNS Drugs (2008) 1.24
The mGluR2 positive allosteric modulator BINA decreases cocaine self-administration and cue-induced cocaine-seeking and counteracts cocaine-induced enhancement of brain reward function in rats. Neuropsychopharmacology (2010) 1.23
Affective and somatic aspects of spontaneous and precipitated nicotine withdrawal in C57BL/6J and BALB/cByJ mice. Neuropharmacology (2008) 1.20
Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats. J Pharmacol Exp Ther (2003) 1.20
Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res (2002) 1.19
Cognitive-disruptive effects of the psychotomimetic phencyclidine and attenuation by atypical antipsychotic medications in rats. Psychopharmacology (Berl) (2007) 1.18
Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats. Neuropsychopharmacology (2005) 1.18
Withdrawal from chronic amphetamine induces depressive-like behavioral effects in rodents. Biol Psychiatry (2003) 1.17
Depression: a repair response to stress-induced neuronal microdamage that can grade into a chronic neuroinflammatory condition? Neurosci Biobehav Rev (2010) 1.17
Prolonged nicotine dependence associated with extended access to nicotine self-administration in rats. Psychopharmacology (Berl) (2004) 1.16
A 'crash' course on psychostimulant withdrawal as a model of depression. Trends Pharmacol Sci (2002) 1.16
Characterization of the effects of bupropion on the reinforcing properties of nicotine and food in rats. Synapse (2003) 1.15
Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer (2011) 1.15
Chronic nicotine administration improves attention while nicotine withdrawal induces performance deficits in the 5-choice serial reaction time task in rats. Pharmacol Biochem Behav (2007) 1.13
Positive modulation of GABA(B) receptors decreased nicotine self-administration and counteracted nicotine-induced enhancement of brain reward function in rats. J Pharmacol Exp Ther (2008) 1.08
Evaluation of reward processes in an animal model of depression. Psychopharmacology (Berl) (2006) 1.07
Circulating tumor cells as emerging tumor biomarkers in breast cancer. Clin Chem Lab Med (2011) 1.06
GABAB receptors in reward processes. Adv Pharmacol (2010) 1.06
Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev (2005) 1.06
Comparative effects of different test day challenges on performance in the 5-choice serial reaction time task. Behav Neurosci (2011) 1.02
The GABAB receptor-positive modulator GS39783 and the GABAB receptor agonist baclofen attenuate the reward-facilitating effects of cocaine: intracranial self-stimulation studies in the rat. Neuropsychopharmacology (2005) 1.02
Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats. Eur J Pharmacol (2006) 1.02
Chronic bupropion differentially alters the reinforcing, reward-enhancing and conditioned motivational properties of nicotine in rats. Nicotine Tob Res (2008) 1.01
Adaptations in cholinergic transmission in the ventral tegmental area associated with the affective signs of nicotine withdrawal in rats. Neuropharmacology (2004) 1.01
Spontaneous nicotine withdrawal potentiates the effects of stress in rats. Neuropsychopharmacology (2007) 1.01
Quantification of circulating miRNAs in plasma: effect of preanalytical and analytical parameters on their isolation and stability. J Mol Diagn (2013) 1.00
Repeated phencyclidine administration alters glutamate release and decreases GABA markers in the prefrontal cortex of rats. Neuropharmacology (2011) 1.00
Animal models and treatments for addiction and depression co-morbidity. Neurotox Res (2007) 0.99
Circulating tumor cells as promising novel biomarkers in solid cancers. Crit Rev Clin Lab Sci (2014) 0.99
Withdrawal from chronic exposure to amphetamine, but not nicotine, leads to an immediate and enduring deficit in motivated behavior without affecting social interaction in rats. Behav Pharmacol (2010) 0.99
Comparison of three molecular assays for the detection and molecular characterization of circulating tumor cells in breast cancer. Breast Cancer Res (2013) 0.99
Recent progress in the synthesis and characterization of group II metabotropic glutamate receptor allosteric modulators. ACS Chem Neurosci (2011) 0.97
Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits. Neuropharmacology (2011) 0.97
N-acetylcysteine decreased nicotine self-administration and cue-induced reinstatement of nicotine seeking in rats: comparison with the effects of N-acetylcysteine on food responding and food seeking. Psychopharmacology (Berl) (2012) 0.96
The effects of the mGluR5 antagonist MPEP and the mGluR2/3 antagonist LY341495 on rats' performance in the 5-choice serial reaction time task. Neuropharmacology (2006) 0.96
Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats. Neuropharmacology (2006) 0.95
Non-nicotinic neuropharmacological strategies for nicotine dependence: beyond bupropion. Drug Discov Today (2003) 0.94
Conditioned facilitation of brain reward function after repeated cocaine administration. Behav Neurosci (2003) 0.94
Molecular characterization of circulating tumor cells in breast cancer: challenges and promises for individualized cancer treatment. Cancer Metastasis Rev (2012) 0.93
Role of α7- and β4-containing nicotinic acetylcholine receptors in the affective and somatic aspects of nicotine withdrawal: studies in knockout mice. Behav Genet (2011) 0.92
Mild anxiogenic effects of nicotine withdrawal in mice. Eur J Pharmacol (2005) 0.92
Low dose cocaine self-administration transiently increases but high dose cocaine persistently decreases brain reward function in rats. Eur J Neurosci (2003) 0.92
Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2010) 0.92
Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration. Psychopharmacology (Berl) (2008) 0.91
Comparison of the effects of the GABAB receptor positive modulator BHF177 and the GABAB receptor agonist baclofen on anxiety-like behavior, learning, and memory in mice. Neuropharmacology (2013) 0.91
High prevalence of autonomous cortisol and aldosterone secretion from adrenal adenomas. Clin Endocrinol (Oxf) (2009) 0.91
The metabotropic glutamate 2/3 receptor agonist LY379268 induces anxiety-like behavior at the highest dose tested in two rat models of anxiety. Eur J Pharmacol (2013) 0.90
Design and synthesis of an orally active metabotropic glutamate receptor subtype-2 (mGluR2) positive allosteric modulator (PAM) that decreases cocaine self-administration in rats. J Med Chem (2010) 0.90
Extended access to methamphetamine self-administration affects sensorimotor gating in rats. Behav Brain Res (2010) 0.90
Long-term effects of chronic intermittent ethanol exposure in adolescent and adult rats: radial-arm maze performance and operant food reinforced responding. PLoS One (2013) 0.90
The metabotropic glutamate 2/3 receptor agonist LY379268 blocked nicotine-induced increases in nucleus accumbens shell dopamine only in the presence of a nicotine-associated context in rats. Neuropsychopharmacology (2011) 0.90
Increased GABA neurotransmission via administration of gamma-vinyl GABA decreased nicotine self-administration in the rat. Synapse (2002) 0.89
The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice. Psychopharmacology (Berl) (2010) 0.89
Withdrawal from chronic phencyclidine treatment induces long-lasting depression in brain reward function. Neuropsychopharmacology (2003) 0.88
Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal. Psychopharmacology (Berl) (2011) 0.88
Neural substrates of psychostimulant withdrawal-induced anhedonia. Curr Top Behav Neurosci (2010) 0.88
Heterozygous reeler mice exhibit alterations in sensorimotor gating but not presynaptic proteins. Eur J Neurosci (2008) 0.88
Inactivation of the 5-HT(7) receptor partially blocks phencyclidine-induced disruption of prepulse inhibition. Biol Psychiatry (2007) 0.88
Metabotropic glutamate 2/3 receptor activation induced reward deficits but did not aggravate brain reward deficits associated with spontaneous nicotine withdrawal in rats. Biochem Pharmacol (2007) 0.87
Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: relevance to smoking in schizophrenia patients. Behav Genet (2004) 0.87
Decreased prepulse inhibition during nicotine withdrawal in DBA/2J mice is reversed by nicotine self-administration. Eur J Pharmacol (2003) 0.87
Withdrawal from chronic cocaine administration induces deficits in brain reward function in C57BL/6J mice. Behav Brain Res (2011) 0.87
Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann N Y Acad Sci (2006) 0.87
Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats. Eur J Pharmacol (2010) 0.87
Patterns of responding differentiate intravenous nicotine self-administration from responding for a visual stimulus in C57BL/6J mice. Psychopharmacology (Berl) (2010) 0.86
Both the shell of the nucleus accumbens and the central nucleus of the amygdala support amphetamine self-administration in rats. Pharmacol Biochem Behav (2002) 0.86
The alpha2 adrenergic receptor antagonist idazoxan, but not the serotonin-2A receptor antagonist M100907, partially attenuated reward deficits associated with nicotine, but not amphetamine, withdrawal in rats. Eur Neuropsychopharmacol (2010) 0.86